BJC Reports最新文献_第2页

Survival benefit of cytoreductive surgery in patients with primary stage IV endometrial cancer: a systematic review & meta-analysis 原发性 IV 期子宫内膜癌患者接受细胞减灭术的生存获益：系统综述与荟萃分析

BJC Reports Pub Date : 2024-10-08 DOI: 10.1038/s44276-024-00084-4

Eveline Ngoc Bao Pham, Nanda Horeweg, Jacolien van der Marel, Linda Suzanne Nooij

{"title":"Survival benefit of cytoreductive surgery in patients with primary stage IV endometrial cancer: a systematic review & meta-analysis","authors":"Eveline Ngoc Bao Pham, Nanda Horeweg, Jacolien van der Marel, Linda Suzanne Nooij","doi":"10.1038/s44276-024-00084-4","DOIUrl":"10.1038/s44276-024-00084-4","url":null,"abstract":"This systematic review and meta-analysis aimed to investigate the survival outcomes following cytoreductive surgery (CRS) in patients with primary stage IV endometrial cancer (EC). We systematically searched the Cochrane Library, Embase, MEDLINE/PubMed, and Web of Science for original studies reporting survival outcomes of primary stage IV EC after complete, optimal, and incomplete CRS. Pooled hazard ratios (HRs) for overall survival (OS) comparing optimal CRS with incomplete CRS were calculated using a random-effects model. Heterogeneity was assessed using the I2 and the Q-test. Twelve studies, including 748 patients, were analysed. 187 patients underwent complete CRS, and 146 patients optimal CRS. Ten studies reported a significant OS benefit after complete (18–48 months) and optimal CRS (13–34 months) compared to incomplete CRS (7–19 months). A benefit was also observed in patients with serous EC or extra- abdominal metastasis. Meta-analysis showed improved OS after complete/optimal vs. incomplete CRS (HR = 0.38, 95% CI 0.21–0.69, p = 0.0016). Heterogeneity was substantial between studies (I2 = 76.7%, p < 0.0001). Our study supports considering CRS in all patients with primary stage IV EC if complete resection is deemed feasible, while also emphasizing the importance of weighing the harms and benefits of this extensive treatment and adopting shared decision-making. CRD42022302968 on May 10th, 2022.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00084-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142415416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Head and neck cancer mortality in the United States: Regional differences in hospice use and place of death 美国头颈部癌症死亡率：使用临终关怀服务和死亡地点的地区差异

BJC Reports Pub Date : 2024-10-08 DOI: 10.1038/s44276-024-00101-6

Melissa C. White, Julia E. Canick, Tariq M. Omer, Justin M. Barnes, William T. Reed, Rebecca L. Rohde, Dina K. Abouelella, Eric Adjei Boakye, Katherine Ramos, Russel R. Kahmke, Nosayaba Osazuwa-Peters

{"title":"Head and neck cancer mortality in the United States: Regional differences in hospice use and place of death","authors":"Melissa C. White, Julia E. Canick, Tariq M. Omer, Justin M. Barnes, William T. Reed, Rebecca L. Rohde, Dina K. Abouelella, Eric Adjei Boakye, Katherine Ramos, Russel R. Kahmke, Nosayaba Osazuwa-Peters","doi":"10.1038/s44276-024-00101-6","DOIUrl":"10.1038/s44276-024-00101-6","url":null,"abstract":"With more than 15,000 annual deaths from head and neck cancer (HNC), an important aspect of end-of-life care for these patients is place of death. Recent evidence suggests an increasing preference for home/hospice at end of life; however, it is unclear whether there is variation in home/hospice use based on region or urban status. We described differences in the place of death of HNC patients based on their region and urban status. Using the CDC WONDER (Wide-Ranging Online Data for Epidemiologic Research) database for HNC mortality (1999 to 2019), place of death was dichotomized as home/hospice vs. other, by Health and Human Services (HHS) region (Regions 1-10), and by urbanization status. Multivariable logistic regression analyses estimated odds of place of death being home/hospice, and being urban/metro, adjusting for both clinical and nonclinical variables. Over the study period, there were 260,630 deaths, 47.4% of which were at home or hospice. Compared to patients in New England/Region 1 (CT, ME, MA, NH, RI, and VT), HNC patients were more likely to die at home/hospice in the Pacific Northwest/Region 10 (AK, ID, OR, WA) (aOR (1.73; 95% CI: 1.64, 1.83) and less likely in the Eastern Section/Region 2 (NJ, NY, PR, VI) (aOR 0.93; 95% CI: 0.89, 0.97). Further, large central metro areas had significantly lower rates of dying at home/hospice than did all other settings. Patients in moderately urban areas were reported to have the greatest use of hospice services and at-home death; patients in the HHS Region representing Alaska, Idaho, Oregon, and Washington were also found to have the highest rates of use. These differences in hospice care should be considered when clinicians counsel patients on their end-of-life options.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00101-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142415398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors 上皮实体瘤中 BRAF III 类突变的治疗弱点和泛癌症格局

BJC Reports Pub Date : 2024-10-08 DOI: 10.1038/s44276-024-00086-2

Eylül Özgü, Benjamin G. Kaplan, Smruthy Sivakumar, Ethan S. Sokol, Esranur Aydın, Ünal Metin Tokat, Ashkan Adibi, Ebru Gül Karakoç, Jiancheng Hu, Razelle Kurzrock, Mutlu Demiray

{"title":"Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors","authors":"Eylül Özgü, Benjamin G. Kaplan, Smruthy Sivakumar, Ethan S. Sokol, Esranur Aydın, Ünal Metin Tokat, Ashkan Adibi, Ebru Gül Karakoç, Jiancheng Hu, Razelle Kurzrock, Mutlu Demiray","doi":"10.1038/s44276-024-00086-2","DOIUrl":"10.1038/s44276-024-00086-2","url":null,"abstract":"Kinase-impaired class III BRAF mutations have recently received attention as a possible prognostic factor and therapeutic target. Class III BRAF variants differ from class I and class II mutations in terms of mechanism of pathway activation and therapeutic vulnerabilities. Genomic landscape analyses of tumors in large real-world cohorts represent a great opportunity to further characterize tumor-related molecular events and treatment vulnerabilities, however, such data is not yet available for tumors with BRAF class III mutations. We investigated the pan-cancer genomic landscape of BRAF class III mutations in 376,302 patients. Patients had comprehensive genomic profiling either by FoundationOne® or FoundationOne®CDx from formalin-fixed, paraffin embedded tissue biopsies. 2 patient cases that harbored BRAF class III mutations who demonstrated dramatic response to anti-EGFR treatment were presented. BRAF class III mutations are likely to co-occur with RAF1, NRAS and HRAS alterations, while concomitant KRAS alterations were rare. Moreover, we found that alterations that predict resistance to anti-EGFR agents were significantly less common in tumors harboring BRAF class III mutations, which is of great importance as anti-EGFR therapies are a potential targeted treatment option in these tumors. Our findings suggest a heterogenous interplay of oncogenic alterations in BRAF class III mutated tumors and have important implications for the molecular mechanisms of carcinogenesis while revealing potential therapeutic vulnerabilities.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00086-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142415407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumour reoxygenation after intratumoural hydrogen peroxide (KORTUC) injection: a novel approach to enhance radiosensitivity 瘤内注射过氧化氢（KORTUC）后的肿瘤复氧：提高放射敏感性的新方法。

BJC Reports Pub Date : 2024-10-08 DOI: 10.1038/s44276-024-00098-y

Samantha Nimalasena, Selvakumar Anbalagan, Carol Box, Sheng Yu, Jessica K. R. Boult, Nigel Bush, Louise Howell, Victoria Sinnett, William Murphy, John Yarnold, Simon P. Robinson, Navita Somaiah

{"title":"Tumour reoxygenation after intratumoural hydrogen peroxide (KORTUC) injection: a novel approach to enhance radiosensitivity","authors":"Samantha Nimalasena, Selvakumar Anbalagan, Carol Box, Sheng Yu, Jessica K. R. Boult, Nigel Bush, Louise Howell, Victoria Sinnett, William Murphy, John Yarnold, Simon P. Robinson, Navita Somaiah","doi":"10.1038/s44276-024-00098-y","DOIUrl":"10.1038/s44276-024-00098-y","url":null,"abstract":"KORTUC (0.5% hydrogen peroxide (H2O2) in 1% sodium-hyaluronate) releases cytotoxic levels of H2O2 in tissues after intratumoural injection. High levels of tumour control after radiotherapy plus KORTUC are reported in breast cancer patients. Here, we use human xenograft models to test the hypothesis that oxygen microbubbles released post-KORTUC are effective in modifying the hypoxic tumour microenvironment. Pimonidazole and Image-iT™ Red (live hypoxia marker) were utilised to assess dose-dependent changes in hypoxia post-H2O2 in HCT116 and LICR-LON-HN5 spheroids. Using a dual 2-nitroimidazole-marker technique and phospho-ATM we evaluated changes in hypoxia and reactive oxygen species (ROS) respectively, in HCT116 and LICR-LON-HN5 xenografts following intratumoural KORTUC. A significant reduction in Image-iT™ Red fluorescence was observed in spheroids 1 h post-H2O2 at ≥1.2 mM, maintained at 24 h. Ultrasound demonstrated sustained release of oxygen microbubbles within tumours, 1 h post-KORTUC. Hypoxia markers demonstrated significant tissue reoxygenation in both models post-KORTUC and significantly increased phospho-ATM foci reflecting increased ROS production. Intratumoural KORTUC represents a novel oxygen delivery method, which can be exploited to enhance radiation response. If efficacy is confirmed in the ongoing phase 2 breast trial it could improve treatment of several tumour types where hypoxia is known to affect radiotherapy outcomes.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11461272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast cancer risk assessment based on susceptibility genes and polygenic risk score in Vietnamese women 基于易感基因和多基因风险评分的越南妇女乳腺癌风险评估

BJC Reports Pub Date : 2024-10-08 DOI: 10.1038/s44276-024-00100-7

Dao Nguyen Vinh, Thanh Thi Ngoc Nguyen, Tuan-Anh Nguyen Tran, Phuoc-Loc Doan, Van-Anh Nguyen Hoang, Minh-Duy Phan, Hoa Giang, Hoai-Nghia Nguyen, Hue Thi Nguyen, Lan N. Tu

{"title":"Breast cancer risk assessment based on susceptibility genes and polygenic risk score in Vietnamese women","authors":"Dao Nguyen Vinh, Thanh Thi Ngoc Nguyen, Tuan-Anh Nguyen Tran, Phuoc-Loc Doan, Van-Anh Nguyen Hoang, Minh-Duy Phan, Hoa Giang, Hoai-Nghia Nguyen, Hue Thi Nguyen, Lan N. Tu","doi":"10.1038/s44276-024-00100-7","DOIUrl":"10.1038/s44276-024-00100-7","url":null,"abstract":"Breast screening recommendation based on individual risk assessment is emerging as an alternative approach to improve compliance and efficiency to detect breast cancer (BC) early. In Vietnam, prior knowledge to stratify risk based on genetic factors is currently lacking. This study recruited 892 BC patients and 735 healthy Vietnamese women from 2016 to 2021. DNA from blood samples of BC patients was first analyzed for pathogenic variants associated with hereditary breast and ovarian cancer syndrome (HBOC). For patients with no HBOC and healthy participants, DNA was genotyped for 398 BC susceptibility single-nucleotide polymorphism (SNPs) by next-generation sequencing to identify significantly associated SNPs and construct a polygenic risk score (PRS). The prevalence of HBOC predisposition gene mutations in Vietnamese women with BC was 5.4%. HBOC cases were significantly younger and enriched in the age group of 20–39 years old. In patients with no HBOC, we found 36 SNPs significantly associated with BC that were mostly similar to other Asian ethnicities; 34 of them were used to build a PRS model achieving an area under the receiver operating characteristics curve of 0.61 (95% CI: 0.56–0.68). Women in the top 1% PRS percentile had an odds ratio of 5.09 (95% CI: 3.10–7.86) while those in the bottom 1% had an odds ratio of 0.21 (95% CI: 0.09–0.39) to develop BC. This study provides the first large datasets for HBOC gene analysis, BC susceptibility SNP association testing, and PRS modeling for Vietnamese women. Together, these data could aid the development of personalized BC screening recommendations for women in Vietnam.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00100-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142415400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer 评论：为什么基因检测在全球未得到充分利用？遗传性乳腺癌的案例

BJC Reports Pub Date : 2024-10-01 DOI: 10.1038/s44276-024-00099-x

Holly J. Pederson, Steven A. Narod

{"title":"Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer","authors":"Holly J. Pederson, Steven A. Narod","doi":"10.1038/s44276-024-00099-x","DOIUrl":"10.1038/s44276-024-00099-x","url":null,"abstract":"It is thirty years since the BRCA1 and BRCA2 genes were discovered and genetic testing for BRCA1 and BRCA2 was introduced. Despite increasing awareness of the genetic basis of cancer and our evolving knowledge of effective means of prevention, screening, and treatment for hereditary breast and ovarian cancers, genetic testing is underutilized, and most mutation carriers remain unidentified. In this commentary, we explore possible reasons for why this might be so. Our focus is on factors that may influence or deter a patient from pursuing testing, rather than discussing the implications of receiving a positive test result. Issues of concern include an inadequate number of genetic counselors, restrictive (and conflicting) eligibility criteria for testing, the cost of the test, health insurance coverage, fear of future insurance discrimination, privacy issues, lack of familiarity with the testing process in primary care and gaps in both patient and provider knowledge about the impact and the value of testing. We discuss how these factors may lead to the underutilization of genetic testing in North America and throughout the world and discuss alternative models of genetic healthcare delivery. We have invited leaders in cancer genetic from around the world to tell us what they think are the barriers to testing in their host countries.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00099-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CNS prophylaxis is (mostly) futile in DLBCL 在 DLBCL 中，中枢神经系统的预防性治疗（大部分）是徒劳的

BJC Reports Pub Date : 2024-10-01 DOI: 10.1038/s44276-024-00087-1

Kevin Shieh, Elizabeth Brem

{"title":"CNS prophylaxis is (mostly) futile in DLBCL","authors":"Kevin Shieh, Elizabeth Brem","doi":"10.1038/s44276-024-00087-1","DOIUrl":"10.1038/s44276-024-00087-1","url":null,"abstract":"Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis, with a median overall survival of approximately five months [1]. The risk for CNS disease has been estimated to be about 5% overall [2], but it is significantly higher in certain high-risk groups [3]. CNS prophylaxis is often administered to patients felt to be at high risk for CNS recurrence. Options for CNS prophylaxis include high-dose methotrexate (HD-MTX) and intrathecal (IT) chemotherapy with methotrexate and/or cytarabine. However, a number of recent retrospective analyses have called into question the efficacy of prophylaxis. Here, we aim to review the literature regarding CNS prophylaxis with HD-MTX or IT chemotherapy in DLBCL. Our review and discussion exclude Burkitt lymphoma and lymphoblastic leukemia/lymphoma, for which standard treatment protocols include CNS prophylaxis. We also exclude double and triple hit lymphoma (DHL, THL) as it is generally accepted that these patients are at a high risk of CNS relapse. Based on the results of several recent studies, we recommend consideration of IT chemotherapy instead of HD-MTX if prophylaxis is desired due to better tolerability. If HD-MTX is desired, it should be done after systemic therapy is completed to avoid treatment delays. We provide an algorithm to guide decision making. However, our review of the literature suggests that CNS prophylaxis by either means has no clear benefit.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00087-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ASSIGN score and cancer risk in the Scottish Heart Health Extended Cohort (SHHEC) study 苏格兰心脏健康扩展队列（SHHEC）研究中的 ASSIGN 评分与癌症风险

BJC Reports Pub Date : 2024-10-01 DOI: 10.1038/s44276-024-00102-5

Catherine A. Fitton, Mark Woodward, Jill JF. Belch

{"title":"ASSIGN score and cancer risk in the Scottish Heart Health Extended Cohort (SHHEC) study","authors":"Catherine A. Fitton, Mark Woodward, Jill JF. Belch","doi":"10.1038/s44276-024-00102-5","DOIUrl":"10.1038/s44276-024-00102-5","url":null,"abstract":"The aim of this work was to determine whether the ASSIGN cardiovascular disease (CVD) score, a 10-year CVD risk score used in primary care in Scotland, could additionally detect cancer risk. 18,107 participants were recruited to the Scottish Heart Health Extended Cohort (SHHEC) study between 1982 and 1995. Information on health and lifestyle were collected, along with blood and urine, and participants were followed up via record linkage to 2017. Cox proportional hazards were used to estimate HRs (95% CIs) for time to cancer diagnosis. A total of 5046 cases of cancer were reported during the follow up period. ASSIGN was significantly associated with a diagnosis of cancer, with a 2.3–3.4% increase in risk of cancer per 1-point increase of ASSIGN. The components of ASSIGN predominantly associated with the risk of cancer were age (HR 1.52; 95% CI 1.48–1.56, cholesterol level (HR 1.11; 95% CI 1.08–1.13), diabetes status (HR 1.24; 95% CI 1.01–1.53), and systolic blood pressure (HR 1.16; 95% CI 1.13–1.19). ASSIGN could be used not only to predict CVD, but also to predict cancer risk in patients. This needs to be validated in further cohorts.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00102-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142360066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone mineral density as a prognostic marker in patients with biliary tract cancer undergoing surgery 作为胆道癌手术患者预后标志的骨矿物质密度

BJC Reports Pub Date : 2024-09-23 DOI: 10.1038/s44276-024-00094-2

Lisa Heinrichs, Georg Fluegen, Sven H. Loosen, Christina Loberg, Linda Wittig, Alexander Quaas, Patrick S. Plum, Nils Große Hokamp, Peter Minko, Andreas Krieg, Gerald Antoch, Wolfram T. Knoefel, Tom Luedde, Christoph Roderburg, Markus S. Jördens

{"title":"Bone mineral density as a prognostic marker in patients with biliary tract cancer undergoing surgery","authors":"Lisa Heinrichs, Georg Fluegen, Sven H. Loosen, Christina Loberg, Linda Wittig, Alexander Quaas, Patrick S. Plum, Nils Große Hokamp, Peter Minko, Andreas Krieg, Gerald Antoch, Wolfram T. Knoefel, Tom Luedde, Christoph Roderburg, Markus S. Jördens","doi":"10.1038/s44276-024-00094-2","DOIUrl":"10.1038/s44276-024-00094-2","url":null,"abstract":"Biliary tract cancer (BTC) is one of the most aggressive malignancies and surgery represents the only curative treatment approach. However, even in patients with complete tumor resection 5-year survival rates are below 30%. So far, prognostic markers to assess the outcome of these patients are lacking. We therefore evaluated bone mineral density (BMD) as a prognostic tool in patients receiving surgery for BTC. 76 BTC patients undergoing tumor resection in our clinic (Duesseldorf cohort) as well as an external validation cohort of 34 BTC patients (Cologne cohort) were included. BMD was analyzed at the first lumbar vertebra, using routine CT scans which has been proven comparable to DXA. Median overall survival (OS) of the Duesseldorf cohort after surgery was 527 days, one- and five-year survival probabilities were 62 and 18%. Patients with BMD above 156.5 HU had significantly improved OS (1435 days vs. 459 days; p = 0.002). The prognostic value for BMD was confirmed using Cox-regression analysis, as well as an external validation cohort. In subgroup analysis the prognostic effect of BMD was only present in female patients, suggesting sex specific differences. BMD is a valuable, easily accessible and independent prognostic marker in patients receiving liver surgery for BTC.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00094-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142313440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001–2020) 头颈部癌症发病率不断上升，但社会人口结构却一成不变：人口流行病学研究（2001-2020 年）

BJC Reports Pub Date : 2024-09-17 DOI: 10.1038/s44276-024-00089-z

Craig D. L. Smith, Alex D. McMahon, Mitana Purkayastha, Grant Creaney, Kelten Clements, Gareth J. Inman, Lesley A. Bhatti, Catriona M. Douglas, Claire Paterson, David I. Conway

{"title":"Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001–2020)","authors":"Craig D. L. Smith, Alex D. McMahon, Mitana Purkayastha, Grant Creaney, Kelten Clements, Gareth J. Inman, Lesley A. Bhatti, Catriona M. Douglas, Claire Paterson, David I. Conway","doi":"10.1038/s44276-024-00089-z","DOIUrl":"10.1038/s44276-024-00089-z","url":null,"abstract":"Increasing incidence of head and neck cancers (HNCs), driven by rising rates of oropharynx cancer (OPC), has been recorded around the world. This study examined trends in HNC and subsites (oral cavity, oropharynx, and larynx cancers) in Scotland focusing on assessing whether the sociodemographic profile has changed over the past 20 years. Scottish Cancer Registry data (2001–2020) including European Age Standardised Rates of HNC and subsites were analysed in multivariate Poisson regression by age, sex, area-based socioeconomic status, and year of diagnosis (with interaction tests). Overall HNC and oral cavity cancer (OCC) incidence remained relatively stable. OPC incidence rates increased by 78%, while larynx cancer incidence declined by 27%. Over time, there were marginal shifts to a slightly older age profile for HNC (p = 0.001) and OCC (p = 0.001), but no changes in OPC (p = 0.86) and larynx cancer (p = 0.29). No shift in the sex profile of HNC was observed except for minor increases in female OCC rates (p = 0.001), and the socioeconomic distribution remained unchanged across all HNC subsites. There have been no significant changes in the sociodemographic profile of HNC in Scotland over the last 20 years, despite the changing trends in HNCs with dramatically increasing incidence rates in OPC and reducing larynx cancer. This information can be used to target or stratify HNC prevention and control.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00089-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0